Abbott Laboratories reports $13.01 billion revenue for quarter ended September 30, 2026, up 14.5%
Abbott Laboratories reported revenue of $13.01 billion for the quarter ended September 30, 2026, an increase of 14.5% from the same quarter a year earlier ($11.37 billion).
For the same period it posted net income of $920 million, down 44%, or $0.53 per diluted share (0.94 a year earlier).
That is a net margin of 7.1%.
On Sanad's AAOIFI Standard 21 screen, Abbott Laboratories is currently compliant: interest-bearing debt is 17.2% of market capitalisation (limit 30%), and impure income is 0.7% of revenue (limit 5%).
Is Abbott Laboratories halal?
See the full AAOIFI screening of Abbott Laboratories
See the full AAOIFI screening of Abbott Laboratories
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.